Internal Investigations and Regulatory Enforcement

• Represented a multinational software corporation in internal investigations of its operations in Greater China in connection with whistleblower allegations, bribery and corruption, revenue recognition, and suspected fraudulent practices.
• Represented the independent audit committee of the board of directors of a U.S. public-listed Chinese corporation in an internal investigation into allegations of financial irregularities.
• Represented the independent audit committee of the board of directors of a U.S. public-listed Chinese corporation in an internal investigation into allegations of fraudulent practices.
• Represented a public-listed corporation in China in compliance risk assessment and compliance program testing in connection with its debarment by the Asian Development Bank for fraudulent practices.
• Represented a U.S. public-listed software company in an investigation from the Chinese government against its Chinese subsidiary triggered by an FCPA violation.
• Represented a multinational aerospace company in investigations from multiple governments related to allegations of fraudulent practices, and non-compliant interactions with Chinese government officials through its business partners.
• Represented multinational pharmaceutical and medical device companies in internal investigations relating to suspected bribery misconduct, off-label promotion, sponsorships and grants, bid-rigging, and third party and distributor misconduct.
• Conducted post-closing compliance due diligence on revenue recognition issues on behalf of the Chinese shareholder of a Fortune 500 joint-venture telecommunication company.

Data Advisory and Compliance

• Represented an American multinational technology company on cross-border data transfer and data privacy issue regarding its internal medical institution in China.
• Represented multinational hedge fund and financial services companies in assessing compliance relating to data privacy, data security and cross-border regulatory issues across the U.S., E.U. and Asia.
• Represented multinational luxury companies in conducting data compliance risk assessment and compliance program enhancement in connection with companies’ operations in Greater China.

Life Sciences Regulatory

• Advised a leading global biotech company on its plasma related transactions in China and regulatory agency inspections on GMP compliance.
• Advised multinational pharmaceutical and medical device companies on compliance relating to post-marketing, advertisement, GCP and GMP issues.
• Seconded as legal counsel to a world-leading multinational pharmaceutical company on human genetic resource management and drug development regulatory issues in the Asia-Pacific region.